Literature DB >> 82581

Antigen-induced murine B cell lymphomas. II. Exploitation of the surface idiotype as tumor specific antigen.

G Haughton, L L Lanier, G F Babcock, M A Lynes.   

Abstract

In the accompanying report, we have described the characterization of two unusual murine B cell lymphomas, CH1 and CH2. A heterologous antiserum, which we refer to as "anti-idiotype" serum, has been raised to the detergent-solubilized surface immunoglobulin of CH1. The following criteria have established that this antiserum is specific for the CH1 tumor and that it reacts with V region determinants of the tumor surface IgM: 1) the antiserum reacts with CH1 tumor cells, but not normal mouse lymphoid cells or CH2 tumor cells, in indirect immunofluorescence and C-dependent cytotoxicity testing, 2) capping with the anti-idiotype serum removes all or most of the tumor surface Ig, 3) the antiserum forms a single band of precipitation against serum from CH1 tumor-bearing mice, when tested by double diffusion precipitin analysis, and 4) a single band of precipitation is formed in the electrophoretic migration position of IgM when the anti-idiotype antiserum is tested against serum from CH1 tumor-bearing mice in immunoelectrophoresis. Furthermore, we have demonstrated that this antiserum is useful in monitoring tumor growth and is a potent immunotherapeutic agent. Specifically, 50% of mice injected with a lethal tumor inoculum and given a small dose of anti-idiotype serum 2 days later remain tumor free, whereas all tumor-challenged control mice died within 30 days.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 82581

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  12 in total

1.  How well can an idiotope peptide mimic replace its parent idiotype in a synthetic peptide vaccine?

Authors:  James S Cavenaugh; Hsu-kun Wang; Jiang Sha; Corey Hansen; Kongnara Papangkorn; Richard S Smith; James N Herron
Journal:  Pharm Res       Date:  2004-08       Impact factor: 4.200

Review 2.  Treatment of lymphoid tumors with anti-idiotype antibodies.

Authors:  G T Stevenson; F K Stevenson
Journal:  Springer Semin Immunopathol       Date:  1983

3.  Transplantable B-cell lymphomas in B10. H-2aH-4bp/Wts mice.

Authors:  L L Lanier; L W Arnold; R B Raybourne; S Russell; M A Lynes; N L Warner; G Haughton
Journal:  Immunogenetics       Date:  1982       Impact factor: 2.846

4.  Cross-reactive idiotypes and common antigen binding specificities expressed by a series of murine B-cell lymphomas: etiological implications.

Authors:  C A Pennell; L W Arnold; P M Lutz; N J LoCascio; P B Willoughby; G Haughton
Journal:  Proc Natl Acad Sci U S A       Date:  1985-06       Impact factor: 11.205

5.  Immunotherapy of B lymphoma by anti-idiotype antibodies: characterization of variant tumour cells appearing a long time after the initial tumour inoculation.

Authors:  M Taya; J Haimovich
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

6.  Diversity of immunoglobulin lambda light chain gene usage over developmental stages in the horse.

Authors:  Rebecca L Tallmadge; Chia T Tseng; M Julia B Felippe
Journal:  Dev Comp Immunol       Date:  2014-04-12       Impact factor: 3.636

7.  H-2 control of expression of an idiotype shared by normal B cells and a B-cell lymphoma.

Authors:  G A Bishop; G Haughton
Journal:  Immunogenetics       Date:  1985       Impact factor: 2.846

8.  Mechanisms of tumour cell escape encountered in treating lymphocytic leukaemia with anti-idiotypic antibody.

Authors:  J Gordon; A K Abdul-Ahad; T J Hamblin; F K Stevenson; G T Stevenson
Journal:  Br J Cancer       Date:  1984-05       Impact factor: 7.640

9.  Consumption of monoclonal anti-idiotypic antibody by neoplastic B lymphocytes: a guide for immunotherapy.

Authors:  F K Stevenson; M J Glennie; D M Johnston; A L Tutt; G T Stevenson
Journal:  Br J Cancer       Date:  1984-09       Impact factor: 7.640

10.  Idiotype variant cell populations in patients with B cell lymphoma.

Authors:  W L Carroll; J N Lowder; R Streifer; R Warnke; S Levy; R Levy
Journal:  J Exp Med       Date:  1986-11-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.